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Abstract
Background: In order to identify the challenges resulting from hypertension in a middle income country, this study has
developed probabilistic models to determine the epidemiological and economic burden of hypertension in Mexico.
Methods: Considering a population base of 654,701 reported cases of adults with hypertension, we conducted a
longitudinal analyses in order to identify the challenges of epidemiological changes and health care costs for
hypertension in the Mexican health system. The cost-evaluation method used was based on the instrumentation
technique. To estimate the epidemiological changes for 2015–2017, probabilistic models were constructed according to
the Box-Jenkins technique.
Results: Regarding changes in expected cases for 2015 vs. 2017, an increase of 12 % is expected (p < 0.001). Comparing
the economic impact in 2015 versus 2017 (p < 0.001), there is a 23 % increase in financial requirements. The total
amount for hypertension in 2016 (US dollars) will be $6306,685,320 Of these, $ 2990,109,035 will be as direct costs and $
3316,576,285 as indirect costs.
Conclusions: If the risk factors and care models remain as they are currently in the health system, the financial
consequences will have a major impact on the out-of-pocket users, following in order of importance, on social security
providers and on public assistance providers.
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Background
In the middle-income countries (MICs), hypertension is-
sues are leading public health challenges to the health
system and to society. Hypertension is a health problem
that requires an integrated approach. The increasing
trend in the prevalence of hypertension in recent years
has been constant. It seems that the increase in hyper-
tension cases will continue [1].
In Mexico, the prevalence of hypertension increased
from 26.6 % in 1993 to 31.8 % in 2012 [2]. The impact
of this disease is evident not only on mortality, but also on
morbidity and the quality of life. This morbidity, com-
pared to other chronic diseases, represents an important
burden for individuals and their families, as well as for the
health system and society in general [3].
The observed and forecasted changes in the incidence
of hypertension in adults will generate constant in-
creases in the need for health services [4]. The observed
changes represent a high economic burden for health
systems, in the medium and long term [5].
To date, in middle-income countries, there are no de-
tailed studies of the financial requirements for health
services needed for hypertension in the next years [6].
Thus, having no knowledge of the costs, it is impossible
to develop resource allocation patterns for a more effi-
cient use of hypertension-related expenditures [7].
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The constantly increasing costs of medical care and
the unknown costs of ambulatory case management and
hospital cases, justify the development and use of indica-
tors for the increasing changes in the demand and costs
of case management in the future [8].
The purpose of this study is to identify expected cases
and financial requirements for hypertension during the
2015–2017 period. We highlight the implications of the
economic impact of hypertension on the users’ pockets
and on the providers of health services as one of the
main challenges to be solved by health planners in
resource allocation for public health interventions.
Methods
An evaluative research was carried out, based on a longitu-
dinal design to determine costs, epidemiological changes
and financial requirements to deliver health care for hyper-
tension during the 2015–2017 period. The three-year
period was chosen for the study for several reasons: Projec-
tions with more than 3 years may generate uncertainty in
the number of expected cases and hence are not recom-
mended for strategic planning reasons; the health budget
is revised, adjusted and approved for a three-year period
by members of the Budget Commission of the legislative
power; the inflationary consumer price index, applied to
the direct health costs, is estimated by the Banco de
Mexico, for consecutive periods every 3 years. Thus, to
estimate indirect health costs under the human capital
focus, it is preferable to limit the study to short term
periods [9, 10].
Whereas analysis of economic impact relates to
changes in the demand for services required for ex-
pected cases, case demand concerns the number of cases
that request services and are under treatment and
annual monitoring at each institution of the Mexican
health system. The studied institutions belong to the
public health sector of the Mexican health system: SSA
(services for the uninsured population) and IMSS/
ISSSTE (health care services for the insured population).
(For more details on the health system in Mexico and
the institutions included in the study, see Appendix 1).
The basic protocol of this project was reviewed and eth-
ically approved by the Committee on Health Research of
the National Council of Science and Technology [11].
The demand for expected cases was estimated based
on the following methodological steps [12]:
Step 1. Modeling: a) identification of the tentative
model for the time series, for use in the prediction, b)
checking the quality of the information and number of
observations, and c) analysis of the autocorrelation of
the historical observations.
Step 2. Estimation: a) determination of the estimates of
the parameters, using the least squares criterion, b)
application of an iterative procedure searching for a
sum of squares function, previously specifying the
preliminary estimates of the unknown parameters.
Step 3. Diagnostic check: a) adequacy test, after the
models were fitted to the data, b) analysis of the
difference between the observed and expected results,
c) application of the Box-Pierce chi squared.
Step 4. Prediction: a) selection and design of the
definitive model, b) data processing, c) prediction of
the future values of the time series.
The time series analysis was based on the total annual
cases observed in the last 18 years in each studied insti-
tution. In our study we delimit the record to the 1996–
2013 period, because before 1996, quality standards in
the records were not high. Before 1996, there were no
well trained personnel for the differentiated recording of
cardiovascular diseases according to the International
Classification of Diseases. The population base of the
study included 654 701 cases of hypertension, which
were medically diagnosed, reported in the year prior to
the study (2014). This information was obtained from
the health impairment statistics bulletin of the National
Health System [13]. This is anonymous information that
is used for the purpose of analysis.
Direct costs refer to the average medical costs of
annual case management per patient and for 3 main
complications. Information on health care services was
obtained from the management of standardized cases,
adjusted by type of institution. The standardization and
adjustment by type of institution, were performed with
the application of a discount rate of 2 % annually, based
on the cost of annual average case handling and cost of
inputs (human resources, medicines, healing materials,
utilities, furniture and medical equipment) by type of
institution. In order to control the costs attributable to
hypertension, the cost-evaluation method was designed
according to an instrumentation technique that identi-
fied production and supply functions for each case man-
agement validated by consensus of experts from each
institution. For each function production (medical visit,
hospitalization, diagnostic studies, etc.) to be evaluated,
management of the average case was defined, based on the
disease’s natural history and the results from a shadow
study of all stages of the process which patients go through
when requesting health services for hypertension [14].
The indirect costs were determined using the hu-
man capital model developed for chronic diseases in
Latin America [15]. This model was adjusted and de-
signed to include three categories of costs attributable
to hypertension: premature mortality, permanent and
temporal disability.
To calculate the financial consequences of changes in
demand by type of institution, in optimal scenarios,
Arredondo et al. BMC Public Health  (2015) 15:1106 Page 2 of 7
controlling the effects of inflation, an inflationary index
projected to 2015–2017 was developed and applied, based
on the last Banco de Mexico price index for consumers
[16]. In order to have an overview of the annual direct and
indirect costs of hypertension by item, the analysis was re-
stricted to 2016, since it corresponds to one-half of the
projected time period.
Results
The resulting model for estimating the expected cases of
hypertension was a model with average movement oper-
ator of order 1. The estimated model of prognosis of de-
mand refers to the 2015–2017 period. Historical data
were annual numbers of hypertension cases reported
over the 1996–2013 period. These numbers of cases,
denoted as Y1, Y2,…,Y18, showed an increasing trend
throughout the study period resulting in a slope coefficient
of the trend analysis that was significantly different from
zero (t = −.12). The data also showed a seasonal pattern
with an increasingly higher peak each year, which coincides
with the seasonal factor. Data were log-transformed to
reduce the observed asymmetry. The natural logarithm of
the number of cases is denoted by Y1,Y2,…,Y18.
One can see that the series is non-seasonal due to the
slow decrease in the self-correlation function. After apply-
ing several seasonal and non-seasonal transformations, we
inferred that the seasonal time series can be explained by
the transformation: Zt = Yt - Yt-1 - Yt-12 + Yt-13, having one
seasonal and one non-seasonal effect. Upon analyzing the
self-correlation function, it seems that it cuts the border-
line of statistical significance of zero difference after lag
12. Some peaks are observed for smaller lags, indicating
the need to include a seasonal average movement operator
with some self-regressive operator and/or average move-
ment operator of a smaller order. Based on the analysis of
both functions, the following models are proposed:
MODEL 1. Seasonal average movement operator, order 1
Zτ−δþ ετ−θ1;13 ετ−12
MODEL 2. Seasonal average movement operator, order
1, and non-seasonal average movement operator, order 1
Zτ−δþ ετ−β1;13ετ−12−θ1 ετ þ β1 β1;12 ετ−13
MODEL 3. The same as model 2, but including the mean
MODEL 4. Seasonal self-regressive operator, order 1
Zτ ¼ δþ ϕ 1;12 Zτ−12
MODEL 5. Non-seasonal self-regressive operator, order 1
and seasonal self-regressive operator, order 1
Zτ ¼ δþ ϕ1;12 Zτ−12þ ϕ 1 Zτ‐1−ϕ 1 ϕ 1;13 Zτ‐13
To select among several possible models, it was neces-
sary to estimate each ones’ parameters and to examine
its properties. Model 1, which included only the seasonal
average movement operator, fits the data’s logarithms
with reasonably good results and a self-correlation dif-
ferent from zero in lag 1, thus indicating that the model
may be improved by adding a self-regressive and/or
non-seasonal average movement operator.
Besides the seasonal average movement operator,
model 2 included the non-seasonal average movement
operator, which showed quite significant improvement
in the standard deviation value that decreased from .4798
to .38007, and no nonzero self-correlation of residuals.
The discussion on model 3 is carried out after discussing
predictions. Models 4 and 5, which included seasonal and
non-seasonal self-regressive operators, were also tested
and were discarded because they did not meet adequacy
conditions (substantially greater values of the Box-Pierce
Chi-square and of standard deviation than in the other
two models). The model that adequately depicted the
series to estimate hypertension cases was the following:
Zτ ¼ δþ ετ−β1;13 ετ−13−θ1 ετ−1 þ θ1 θ1;12 ετ−13
with the prediction equation:
γþτ ¼ δþ γτ−13 þ β1;12 ετ−13−θ1 ετ−1
þ θ1 θ1 ;12ετ−13 þ ετ
Therefore, the proposed model was model 3, which
besides average movement and seasonal average move-
ment operators, includes the mean estimator and variables
mentioned in the methodology section. The outcomes of
this model were better than those obtained using model 2
(lower standard error) whereas the t value for the mean
estimator indicates that the trend is negative and signifi-
cantly different from zero (see Table 1).
The findings of expected hypertension cases during
the study period have constant incremental trends in the
population served at the 3 major health institutions in
Mexico (see Table 2). These trends are stronger in the
case of insured population showing an increase for
Table 1 Statistical results of models 2 and 3
Variables Model 2 Model 3
Number of nonseasonal differences 1 1
Number of seasonal differences 0 0
Number of Parameters 2 3
Estimator A .2579 (2.43) .7689 (4.01)
Estimator B -.2723 (−2.54) .5536 (2.23)
Estimator C .8599 .9123
Box-Pierce Chi-square 22.25 14.67
Standard deviation 24.22 26.9
Nonzero correlations 0 0
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2015–2017 (p < 0.001). Adding up the cases that increase
annually by type of institution, the result is 72895 cases
for the insured population (IMSS and ISSTE) vs 38109
cases for the uninsured population (SSA).
The results on case management costs and on finan-
cial requirements to satisfy the demand for hypertension
services in the coming years (see Tables 3 and 4) are
new, pertinent and relevant evidence for an efficient
management of hypertension in the near future in
Mexico. Table 3 describes the main results of the expected
costs and financial requirements for each year of the study
(2015–2017) for the entire health system. Table 4 de-
scribes the expected economic burden only for 2016 as a
cut-off point, differentiating costs by type of cost, type of
institution and type of complication.
Comparing the economic impact in 2015 with the
forecast for 2017 (p < 0.001), a 21 % increase in financial
requirements has been forecasted (see Table 2). The total
cost for hypertension in 2016 is forecasted to be US
$6306,685,320 (see Table 3). This includes $2990,109,035
in direct costs and $3316,576,285 in indirect costs. The
total costs for each institution are: $926,982,959 for
the Ministry of Health, serving the uninsured popula-
tion; $2163,295,383 for the insured population (the
Mexican Institute for Social Security, and the Institute
for Social Security and Services for State Workers); and
$3216,406,987 for the out-of-pocket users. Nephropathy is
the largest single contributor to the total cost of overall
management ($1036,073,067). This is followed by the costs
of treating nonfatal myocardial infarction ($470,942,093)
and nonfatal stroke ($376,753,221).
The overall contribution of direct costs was 47 % of
total costs and indirect costs were 53 %. With regard to
the four categories of estimated direct costs, results
were: consultations and diagnoses, 12 %; drugs, 14 %;
hospitalizations, 11 %; and complications, 63 %. Distri-
bution of total costs of complications was as follows:
nephropathy, 55 %; nonfatal myocardial infarction, 25 %;
and nonfatal stroke, 20 %. Results for the three estimated
categories of indirect costs were: mortality costs, 15 %;
costs of permanently disabled patients, 74 %; and costs of
temporarily disabled patients, 11 % (see Table 3).
The institution for the insured population was found
to have the highest average direct costs per managed
case, as well as the highest economic impact of global
management of hypertension for 2015–2017. Financial
requirements for health care services for hypertension
represent 19.5 % of the total budget assigned to the un-
insured population, and 12.5 % of that allocated to the
insured population.
Discussion
This study addressed the need to generate information
that is necessary, relevant and pertinent, for a more stra-
tegic planning of public health actions that are oriented
towards a better management of chronic diseases such
as hypertension. The estimation of expected cases and fi-
nancial requirements for each year of the studied period
and for each of the main institutions of the health system
in Mexico represents one of its main contributions.
The finding related to the high contribution of patients
and families to the total expenditure for hypertension in
Mexico, is a fact that was unknown for this indicator.
The constant increase in both epidemiological changes and
the economic burden of hypertension, represents a very
important finding that can be applied to the analysis of this
problem in middle-income countries like Mexico, as well
as in other Latin American countries, because of the great
similarity of the health systems and epidemiological
changes in chronic diseases in all these countries [17].
With respect to the differences in expected costs and
financial requirements for the insured health subsystem
vs. the uninsured subsystem, the differences in these re-
sults are mainly due to 3 reasons: The costs of inputs
for social security institutions are higher, the population
seeking care for hypertension is greater in uninsured
care centers and because of differences in standards of
quality of care and input mix in each institution.
Table 2 Expected cases for hypertension in Mexico to the period 2015–2017 by type of institution
Type of
institution
Number of cases per year
2015 2016 2017 p value
SSA 291904 306896 330013 <0.001
CIa (284048–299760) (298896–314896) (321501–338525)
IMSS 324447 348903 374603 <0.001
CIa (315782–333112) (339591–358215) (366890–382316)
ISSSTE 133350 144233 156089 <0.001
CIa (127669–139061) (137383–151083) (149589–163589)
Source: Arredondo et al. (2014) [17] Costos y consecuencias financieras del cambio en el perfil epidemiológico en México. INSP–University of Montreal-International
Development Research Centre, 1999–2013. Update of probabilistic models, January 2015
Box–Pierce statistical test (P < 0.001)
SSA Ministry of Health, IMSS Mexican Institute for Social Security, ISSSTE Institute for Social Security and Services for State Workers
a95 % CIs
Arredondo et al. BMC Public Health  (2015) 15:1106 Page 4 of 7
There are also several studies of epidemiological
trends in recent years but in very general terms, they do
not specify the disease or the expected epidemiological
trends for the expected cases in the future. Our results
have similarities, in terms of constant incremental
pressure trends, with other case studies published by dif-
ferent authors [18, 19], particularly with hypertension re-
sults of the last national health survey conducted in
Mexico in 2013 [20]. Indeed, a tendency is expected for a
constant increase in the required health care services and
Table 3 Cost from epidemiological changes of hypertension expected for the years 2015, 2016, 2017 in Mexico (in US$)
Item cost Year
2015 2016 2017 p value
Direct costs
Consultations/diagnosis 342,503,700 358,813,400 391,432,800 <0.001
Drugs 399,587,467 418,615,441 456,671,390 <0.001
Hospitalization 313,961,277 328,911,814 358,812,888 <0.001
Nephropathy 988,978,836 1,036,073,067 1,130,261,527 <0.001
Nonfatal myocardial infarction 449,535,634 470,942,093 513,755,010 <0.001
Nonfatal stroke 359,628,074 376,753,221 411,003,513 <0.001
Total direct costs 2854,194,988 2,990,109,035 3,261,937,129 <0.001
Indirect costs
Mortality 474,872,870 497,485,864 542,711,851 <0.001
Permanent disability 2342,709,670 2,454,267,274 2,677,382,480 <0.001
Temporary disability 348,240,277 364,823,148 397,988,888 <0.001
Total indirect costs 3,165,822,818 3,316,576,285 3,618,083,220 <0.001
TOTAL COSTS 6,020,017,806 6,306,685,320 6,880,020,349 <0.001
Source: Arredondo et al. (2014) [17] Costos y consecuencias financieras del cambio en el perfil epidemiológico en México. INSP–University of Montreal-International
Development Research Centre, 1999–2009. Update of probabilistic models, January 2015
Box–Pierce statistical test (P < 0.001)
Exchange rate: January 2015, 1 US$ = 14.85 Mexican $
Table 4 Direct, indirect and total costs (in US$) for health care service providers and users attributable to hypertension expected for
the year 2016 in Mexico
Item of cost
SSAa IMSS ISSSTE Users TOTAL
Direct costs
Consultations/diagnosis 45,733,525 87,930,959 35,154,160 182,994,757 358,813,400
Drugs 61,522,443 102,586,116 41,013,184 213,493,698 418,615,441
Hospitalisation 48,339,063 80,603,376 32,224,645 167,744,730 328,911,814
Nephropathy 152,268,051 253,900,637 101,507,633 528,396,746 1,036,073,067
Nonfatal myocardial infarction 69,212,750 115,409,380 46,139,832 240,180,130 470,942,093
Nonfatal stroke 55,370,201 92,327,505 36,911,866 192,143,650 376,753,221
Total direct 439,446,033 732,757,971 292,951,320 1,524,953,711 2,990,109,035
Indirect costs
Mortality 73,130,538 121,884,230 35,752,658 253,717,405 497,485,864
Permanent disability 360,777,319 601,295,532 240,518,212 1,251,676,210 2,454,267,274
Temporary disability 53,629,060 89,381,768 48,753,692 186,059,662 364,823,148
Total indirect 487,536,917 812,561,530 325,024,561 1691,453,277 3316,576,285
Total costs 926,982,959 1545,319,501 617,975,882 3216,406,987 6,306,685,320
Source: Arredondo et al. (2014) [17] Costos y consecuencias financieras del cambio en el perfil epidemiológico en México. INSP–University of Montreal-International
Development Research Centre, 1999–2009. Update of probabilistic models, January 2015
Exchange rate: January 2015, 1 US$ = 14.85 Mexican $
aSSA Ministry of Health, IMSS Mexican Institute for Social Security, ISSSTE Institute for Social Security and Services for State Workers, Users pocket payment
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in costs, although the increase is greater for the insured
population than for the uninsured population.
On the other hand, there is much talk about the high
health expenditures of patients in MICs, but the exact
measurement of expenditures by families and patients
with chronic health conditions like hypertension, is not
being considered. Our results certainly provide informa-
tion about the high health expenditure by patients,
attributable to hypertension.
In addition to some problems listed in the methods
section, this study also suffers several more external lim-
itations. First, on the epidemiological analysis of the fre-
quency of cases, we only included cases of hypertension
and co-morbidity of 3 main complications that required
health services for diagnosis, treatment and control, in
major health institutions in Mexico. In this sense, the
analysis does not include cases of patients ignoring
hypertension symptoms, or even knowing they are ill
but cannot have access to health services for different
reasons. Second, the main limitation of the time series
analysis, using the Box-Jenkins method, is the great
number of reports that are required, having high quality
information on observed cases (15 years minimum), for
a rigorous estimate of expected cases in future years.
Our study covers an 18 year period (1996–2013), since
before 1996, quality standards in the records were not
high enough; However, there may be important limita-
tions when trying to replicate our forecasting model in
other middle income countries where the quality of the
information may not be good enough in terms of the
minimum number of annual observations that is required.
With respect to indirect costs, another limitation of
this study, based on the human capital focus, is the pos-
sible overestimation of indirect costs, attributable to
temporary disability, when friction costs are not deter-
mined. In the short-medium term, the indirect costs
could be overestimated due to the fact that the patients
may compensate for the loss of production in the long
term, if they return to their job, or their work may be
carried out by their co-workers. In the long term, the
indirect costs could be zero if the patient improves and
returns to his/her job, or else if an unemployed worker
took his/her place at work after a “friction period,” in
which case, costs must be included that relate to search-
ing for and training the unemployed worker in his/her
new position; this depends on the unemployment rate
and disability work policies, such as those proposed by
some authors [21]. However, in our study, indirect costs
were limited to a 3-year period and it is not the objective
of our study to disaggregate the effect of other variables.
Conclusions
This study estimated the changes in the number of ex-
pected hypertension cases during the 2015–2017 period,
in a middle income country. Direct and indirect costs
were also identified for the management of an average
hypertension case and its 3 main complications. The re-
sults are proposed as relevant information for decision-
making in the planning and allocation of resources for
health services for chronic diseases in Mexico. This is an
example of what is happening in the management of
hypertension in middle income countries.
The study’s results also reveal important evidence of
the economic burden for the users’ pockets coming from
hypertension management. In this sense, and in the con-
text of the health reforms in MICs such as Mexico, as-
pects such as equity and access to health services are
still an unresolved challenge.
Appendix 1: Some considerations on Mexico’s
health system
At their inception, in 1942, health policies in Mexico
were put into effect by municipal actions oriented by the
Consejo Superior de Salubridad (Higher Council for
Health). These actions proved to be clearly deficient. An
office of the Federal Executive had to be created, with suf-
ficient power to allocate resources and regulate activities
to control epidemics and improve urban sanitation. The
Departamento de Salubridad (Department of Health) was
created, supported by the Consejo de Salubridad General
(Council for General Health) which served, along with
legislative agencies, as the advisory and managing bodies
to issue specific health interventions. Until 1929, this
policy allowed for the implementation of Health Coopera-
tive Units (primary health centers) working with states
and municipalities.
During the 30’s, health policies that had been set dur-
ing the revolutionary period (1910–1920) were still
followed. In addition, a new health care model was cre-
ated: joint health services offered by the government,
agricultural development banks and peasants endowed
with vast land extensions. Under this new policy, the
Department of Health worked to start and maintain in-
tensive care and curative care services. The new health
policy became quite dynamic on account of government
support for health services for workers.
The foundation of the present health system can be
traced to 1943, the year in which IMSS and the SSA
were established to convey tripartite contributions (state,
enterprises and workers’ funds) to support the industrial
development of the main cities and the public supply of
comprehensive services. This model prevailed almost
worldwide; its technical core was drawn from the Inter-
national Labor Organization. The SSA arose from the
fusion of the Secretaría de Asistencia (Welfare Secretariat)
and the Departamento de Salubridad (Department of
Health). Its healthcare mission was extended to provide
more comprehensive care for the population left
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unprotected by social security, which included the major-
ity of peasants, the unemployed, and informal economy
workers. SSA was also in charge of launching massive
campaigns to control epidemics and specific health
problems. An additional advancement of this period
was the creation of ISSSTE in 1959, which brought to-
gether the diversity of pension and fringe benefit sys-
tems for state workers.
Presently, according to data from the 2003–2018
National Health Program, the Mexican public health sys-
tem provides care for 90 % of the population and is
mainly formed by the three health institutions which
were included in this study. It is important to highlight
the fact that IMSS provides services for the insured
population and covers 45 % of the population, ISSSTE
serves the insured population of state workers and covers
approximately 5 % of the population. Finally, since last
years, the SSA in the context of universal coverage re-
forms, implemented as the main strategy program ‘Seguro
Popular’, a program to cover the uninsured population,
which is 40 % of the population. The remaining 10 % are
served by the private health provider.
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